FORMAC obtains EMA Orphan Drug Designation for FP110
This Orphan Drug Designation follows a similar decision from the Food & Drug Administration (FDA). It is another important milestone for the program, following the promising results obtained during a phase 2A clinical trial with patients suffering from pouchitis. Pouchitis is a debilitating condition for which there is no approved treatment and the EMA's decision also reflects the high unmet medical need for patients suffering from this condition.
"We made excellent progress in securing the additional clinical data ", says Jan Rosier, FORMAC's Chief Executive Officer, "and we have started negotiations with identified potential partners to make this promising and important product available to patients".
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.